16.11.2010 • NewsNovartisAlconNestlé

Novartis Hasn't Ruled out Keeping its 77% Alcon Stake

Swiss drugmaker Novartis  has not ruled out sticking with its 77% stake in U.S.-listed eyecare group Alcon, Novartis Chief Executive Joe Jimenez was quoted as saying on Tuesday.

"The intention is to have 100%. But Nestle owned 77%, and the company was run very successfully for many years, so we have not ruled that out," Jimenez said in an interview with the Financial Times published a day ahead of Novartis' investor day on Wednesday.

Novartis, which completed its buy of the 77% stake from Nestle earlier this year, is offering Alcon minority shareholders 2.8 Novartis shares for each Alcon share, an offer Alcon's Independent Director Committee has repeatedly rebuffed as too low.

Novartis has said it could use Swiss merger law to help it push through the deal.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.